Clinical Trials Logo

Clinical Trial Summary

forty DLE lesions from patients will be recruited in the study. The lesions on one side of the body were block-randomized into the treatment group and the other side served as a control. The patients can continue their systemic treatments and the PDL is designed to be used as an adjunctive treatment. Treatments with the PDL will be delivered in the treatment group every 4 weeks for 4 consecutive months while the lesions in the control group received a sham. The patients will be evaluated at baseline (week 0), week 4, 8, 12, and at follow-up period of 4, 12 weeks after the final treatment (week 16, 24). Erythema index (EI), Texture index (TI) will be obtained and digital photographs will be taken and modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI) will be assessed in every visit. The digital photographs will later be evaluated by 3-blinded dermatologists. Moreover, side effects and patients' satisfaction score will also be recorded.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03178188
Study type Interventional
Source Chulalongkorn University
Contact Pawinee Rerknimitr, MD
Email pawineererk@yahoo.co.th
Status Recruiting
Phase Phase 2/Phase 3
Start date December 15, 2016
Completion date December 14, 2017

See also
  Status Clinical Trial Phase
Completed NCT02034344 - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Phase 0
Completed NCT01858792 - A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies N/A
Withdrawn NCT00222183 - Cutaneous Lupus Erythematosus and Elidel N/A
Recruiting NCT04857034 - A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Phase 2
Completed NCT01845740 - Phase Ib Study of SC Milatuzumab in SLE Phase 1
Completed NCT02656082 - Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Phase 2
Terminated NCT02428309 - Autologous Polyclonal Tregs for Lupus Phase 1
Completed NCT01597050 - Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Phase 2
Completed NCT01923415 - A Non-drug Study Profiling Cutaneous Lupus Phase 0